Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 68-73

  Smal, Caroline ^a   Van Den Neste, Eric ^a,b   Maerevoet, Marie ^b   Poiré, Xavier ^b   Théate, Ivan ^b   Bontemps, Françoise ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

B CLL lymphocytes; Deoxycytidine kinase; Immunocytochemistry; Nucleoside analogues; Ser 74 phosphorylation

Indexed keywords

APHIDICOLIN; DEOXYCYTIDINE KINASE; ETOPOSIDE; GENISTEIN; SERINE;

ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIBODIES; DEOXYCYTIDINE KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, B-CELL, CHRONIC; PHOSPHORYLATION; PHOSPHOSERINE; SERINE; TUMOR CELLS, CULTURED;

EID: 34249899423     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.013     Document Type: Article

References (24)

1. Arner E.S., and Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 67 (1995) 155-186
2. Kawasaki H., Carrera C.J., Piro L.D., Saven A., Kipps T.J., and Carson D.A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81 (1993) 597-601
3. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001) 875-890
4. Mackey J.R., Galmarini C.M., Graham K.A., Joy A.A., Delmer A., Dabbagh L., et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 105 (2005) 767-774
5. Smal C., Cardoen S., Bertrand L., Delacauw A., Ferrant A., Van den Berghe G., et al. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem. Pharmacol. 68 (2004) 95-103
6. Csapo Z., Keszler G., Safrany G., Spasokoukotskaja T., Talianidis I., Staub M., et al. Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem. Pharmacol. 65 (2003) 2031-2039
7. Van Den Neste E., Smal C., Cardoen S., Delacauw A., Frankard J., Ferrant A., et al. Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes. Biochem. Pharmacol. 65 (2003) 573-580
8. Smal C., Vertommen D., Bertrand L., Ntamashimikiro S., Rider M.H., Van Den Neste E., et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J. Biol. Chem. 281 (2006) 4887-4893
9. Hatzis P., Al-Madhoon A.S., Jullig M., Petrakis T.G., Eriksson S., and Talianidis I. The intracellular localization of deoxycytidine kinase. J. Biol. Chem. 273 (1998) 30239-30243
10. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
11. Duggan M.J., and Stephenson F.A. Biochemical evidence for the existence of gamma-aminobutyrate A receptor iso-oligomers. J. Biol. Chem. 265 (1990) 3831-3835
12. Spasokoukotskaja T., Arner E.S., Brosjo O., Gunven P., Juliusson G., Liliemark J., et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer 31A (1995) 202-208
13. Csapo Z., Sasvari-Szekely M., Spasokoukotskaja T., Talianidis I., Eriksson S., and Staub M. Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem. Pharmacol. 61 (2001) 191-197
14. Sasvari-Szekely M., Spasokoukotskaja T., Szoke M., Csapo Z., Turi A., Szanto I., et al. Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2′-deoxyadenosine (Cladribine) in human lymphocytes. Biochem. Pharmacol. 56 (1998) 1175-1179
15. Keszler G., Spasokoukotskaja T., Sasvari-Szekely M., Eriksson S., and Staub M. Deoxycytidine kinase is reversibly phosphorylated in normal human lymphocytes. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1147-1151
16. Hubeek I., Peters G.J., Broekhuizen A.J., Talianidis I., Sigmond J., Gibson B.E., et al. Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J. Clin. Pathol. 58 (2005) 695-699
17. Lotfi K., Karlsson K., Fyrberg A., Juliusson G., Jonsson V., Peterson C., et al. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. Biochem. Pharmacol. 71 (2006) 882-890
18. Veuger M.J., Honders M.W., Landegent J.E., Willemze R., and Barge R.M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 96 (2000) 1517-1524
19. Shi J.Y., Shi Z.Z., Zhang S.J., Zhu Y.M., Gu B.W., Li G., et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14 (2004) 759-768
20. van den Heuvel-Eibrink M.M., Wiemer E.A., Kuijpers M., Pieters R., and Sonneveld P. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML). Leukemia 15 (2001) 855-856
21. Veuger M.J., Honders M.W., Willemze R., and Barge R.M. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. Eur. J. Haematol. 69 (2002) 171-178
22. Galmarini C.M., Thomas X., Graham K., El Jafaari A., Cros E., Jordheim L., et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122 (2003) 53-60
23. Mohammad R.M., Beck F.W., Katato K., Hamdy N., Wall N., and Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol. Chem. 379 (1998) 1253-1261
24. Ahmad I., Al-Katib A.M., Beck F.W., and Mohammad R.M. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report. Clin. Cancer Res. 6 (2000) 1328-1332